Related references
Note: Only part of the references are listed.A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Scott L. Friedman et al.
HEPATOLOGY (2018)
Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
Parambir S. Dulai et al.
HEPATOLOGY (2017)
A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis
Jerome Boursier et al.
JOURNAL OF HEPATOLOGY (2017)
Assay-dependent variability of serum insulin concentrations: a comparison of eight assays
Maryam Tohidi et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2017)
Review article: new treatments in non-alcoholic fatty liver disease
S. A. Townsend et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults
Andrea Marengo et al.
CLINICS IN LIVER DISEASE (2016)
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu et al.
GASTROENTEROLOGY (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease
Jerome Boursier et al.
JOURNAL OF HEPATOLOGY (2016)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
Challenges and Opportunities in Drug and Biomarker Development for Nonalcoholic Steatohepatitis: Findings and Recommendations From an American Association for the Study of Liver Diseases-US Food and Drug Administration Joint Workshop
Arun J. Sanyal et al.
HEPATOLOGY (2015)
Current efforts and trends in the treatment of NASH
Vlad Ratziu et al.
JOURNAL OF HEPATOLOGY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease - the role of transient elastography and plasma cytokeratin-18 fragments
R. Kwok et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C
J. Boursier et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease
Kenneth Cusi et al.
JOURNAL OF HEPATOLOGY (2014)
Review article: the diagnosis of non-alcoholic fatty liver disease - availability and accuracy of non-invasive methods
D. Festi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients
Sven M. A. Francque et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States
Michael R. Charlton et al.
GASTROENTEROLOGY (2011)
Endpoints and clinical trial design for nonalcoholic steatohepatitis
Arun J. Sanyal et al.
HEPATOLOGY (2011)
Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings
Elizabeth M. Brunt et al.
HEPATOLOGY (2011)
A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients
R. Anty et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
K. G. M. M. Alberti et al.
CIRCULATION (2009)
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Amy G. Shah et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease
S. A. Harrison et al.
GUT (2008)
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
Paul Angulo et al.
HEPATOLOGY (2007)
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
Richard K. Sterling et al.
HEPATOLOGY (2006)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
Sources of variability in histological scoring of chronic viral hepatitis
MC Rousselet et al.
HEPATOLOGY (2005)
Sampling variability of liver fibrosis in chronic hepatitis C
P Bedossa et al.
HEPATOLOGY (2003)